SG11201610227TA - Pharmaceutical dosage forms - Google Patents

Pharmaceutical dosage forms

Info

Publication number
SG11201610227TA
SG11201610227TA SG11201610227TA SG11201610227TA SG11201610227TA SG 11201610227T A SG11201610227T A SG 11201610227TA SG 11201610227T A SG11201610227T A SG 11201610227TA SG 11201610227T A SG11201610227T A SG 11201610227TA SG 11201610227T A SG11201610227T A SG 11201610227TA
Authority
SG
Singapore
Prior art keywords
dosage forms
pharmaceutical dosage
pharmaceutical
forms
dosage
Prior art date
Application number
SG11201610227TA
Inventor
Stefania Beato
Peggy Quinton
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SG11201610227TA publication Critical patent/SG11201610227TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/45Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2031Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036Silicones; Polysiloxanes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2095Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2813Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • A61K9/2826Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
SG11201610227TA 2014-07-07 2015-07-06 Pharmaceutical dosage forms SG11201610227TA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462021271P 2014-07-07 2014-07-07
PCT/IB2015/055098 WO2016005880A1 (en) 2014-07-07 2015-07-06 Pharmaceutical dosage forms

Publications (1)

Publication Number Publication Date
SG11201610227TA true SG11201610227TA (en) 2017-01-27

Family

ID=53610933

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201610227TA SG11201610227TA (en) 2014-07-07 2015-07-06 Pharmaceutical dosage forms

Country Status (29)

Country Link
US (2) US10143680B2 (en)
EP (2) EP3166596B1 (en)
JP (2) JP6731136B2 (en)
KR (1) KR102468610B1 (en)
CN (1) CN106470704B (en)
AR (1) AR101116A1 (en)
AU (1) AU2015287336B2 (en)
BR (1) BR112016030243B1 (en)
CA (1) CA2954393C (en)
CL (1) CL2017000026A1 (en)
CY (1) CY1120749T1 (en)
DK (1) DK3166596T3 (en)
EA (2) EA201991359A1 (en)
EC (1) ECSP17008187A (en)
ES (1) ES2686704T3 (en)
HR (1) HRP20181406T1 (en)
HU (1) HUE039037T2 (en)
IL (1) IL249374B (en)
LT (1) LT3166596T (en)
MX (1) MX2016017315A (en)
PE (1) PE20170201A1 (en)
PH (1) PH12016502540A1 (en)
PL (1) PL3166596T3 (en)
PT (1) PT3166596T (en)
SG (1) SG11201610227TA (en)
SI (1) SI3166596T1 (en)
TN (1) TN2016000557A1 (en)
TW (1) TWI707682B (en)
WO (1) WO2016005880A1 (en)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191487A1 (en) 2004-03-17 2007-08-16 Rigassi-Dietrich Petra G Galenic formulations of organic compounds
GT200600381A (en) * 2005-08-25 2007-03-28 ORGANIC COMPOUNDS
PE20090015A1 (en) * 2007-03-13 2009-01-30 Takeda Pharmaceutical SOLID PREPARATION
PT2523731T (en) 2010-01-14 2019-01-21 Novartis Ag Use of an adrenal hormone-modifying agent
CN103153286A (en) * 2010-08-27 2013-06-12 沃泰克斯药物股份有限公司 Pharmaceutical composition and administrations thereof
RU2628808C2 (en) * 2011-09-08 2017-08-22 Новартис Аг Application of aromatase inhibitor for treatment of hypogonadism and related diseases
TWI609869B (en) * 2012-01-17 2018-01-01 諾華公司 New forms and salts of a dihydropyrrolo[1,2-c]imidazolyl aldosterone synthase or aromatase inhibitor
WO2013126326A1 (en) 2012-02-21 2013-08-29 Celgene Corporation Solid forms of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione, compositions and methods of use thereof
WO2013153129A1 (en) 2012-04-12 2013-10-17 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern

Also Published As

Publication number Publication date
TN2016000557A1 (en) 2018-04-04
JP2019194221A (en) 2019-11-07
IL249374A0 (en) 2017-02-28
SI3166596T1 (en) 2018-10-30
EA033685B1 (en) 2019-11-15
EA201790140A1 (en) 2017-05-31
ECSP17008187A (en) 2018-03-31
AR101116A1 (en) 2016-11-23
CL2017000026A1 (en) 2017-07-28
EP3412278A1 (en) 2018-12-12
IL249374B (en) 2021-09-30
MX2016017315A (en) 2017-04-27
CN106470704A (en) 2017-03-01
AU2015287336A1 (en) 2017-01-12
PE20170201A1 (en) 2017-04-08
JP2017520590A (en) 2017-07-27
WO2016005880A1 (en) 2016-01-14
KR102468610B1 (en) 2022-11-21
US20170202808A1 (en) 2017-07-20
KR20170029491A (en) 2017-03-15
HUE039037T2 (en) 2018-12-28
US10709691B2 (en) 2020-07-14
AU2015287336B2 (en) 2018-06-14
LT3166596T (en) 2018-09-25
ES2686704T3 (en) 2018-10-19
PL3166596T3 (en) 2018-11-30
HRP20181406T1 (en) 2018-10-19
US10143680B2 (en) 2018-12-04
PT3166596T (en) 2018-10-19
CA2954393C (en) 2022-07-19
BR112016030243A2 (en) 2017-08-22
TW201613586A (en) 2016-04-16
US20190060283A1 (en) 2019-02-28
EP3166596A1 (en) 2017-05-17
EA201991359A1 (en) 2020-03-13
DK3166596T3 (en) 2018-09-10
CN106470704B (en) 2020-07-31
CY1120749T1 (en) 2019-12-11
EP3166596B1 (en) 2018-06-06
JP6731136B2 (en) 2020-07-29
TWI707682B (en) 2020-10-21
CA2954393A1 (en) 2016-01-14
BR112016030243B1 (en) 2023-04-11
PH12016502540A1 (en) 2017-04-10

Similar Documents

Publication Publication Date Title
IL270954A (en) Pharmaceutical compounds
GB201404922D0 (en) Pharmaceutical compounds
SG11201702298VA (en) Pharmaceutical preparation
GB201416513D0 (en) Pharmaceutical compounds
GB201417707D0 (en) Pharmaceutical compounds
IL250160A0 (en) Pharmaceutical agent
SI3236952T1 (en) Pharmaceutical tablet composition
GB201406115D0 (en) New pharmaceutical use
GB201517133D0 (en) New pharmaceutical use
GB201409662D0 (en) New pharmaceutical use
HRP20181406T1 (en) Pharmaceutical dosage forms
GB201508022D0 (en) Pharmaceutical compounds
GB201517454D0 (en) New pharmaceutical use
GB201517132D0 (en) New pharmaceutical use
GB201508613D0 (en) New pharmaceutical use
GB201508611D0 (en) New pharmaceutical use
GB201507813D0 (en) New pharmaceutical use
GB201416969D0 (en) Pharmaceutical compounds
GB201416968D0 (en) Pharmaceutical compounds
GB201416625D0 (en) Pharmaceutical compounds
GB201416627D0 (en) Pharmaceutical compounds
GB201416622D0 (en) Pharmaceutical compounds
GB201404896D0 (en) Pharmaceutical compounds
GB201402278D0 (en) Pharmaceutical compounds
GB201402013D0 (en) Pharmaceutical compounds